Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week Low – Here’s What Happened

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $34.01 and last traded at $33.33, with a volume of 1041 shares. The stock had previously closed at $34.87.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Stock Down 4.7 %

The firm has a market cap of $1.60 billion, a price-to-earnings ratio of 11.09, a price-to-earnings-growth ratio of 1.07 and a beta of 0.81. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a 50-day moving average of $39.34 and a 200-day moving average of $43.97.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares in the company, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,533 shares of company stock worth $1,987,482 in the last 90 days. 27.10% of the stock is currently owned by company insiders.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Aurora Investment Counsel lifted its holdings in shares of Amphastar Pharmaceuticals by 0.4% in the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after buying an additional 232 shares during the period. GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after purchasing an additional 301 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. Finally, nVerses Capital LLC raised its position in shares of Amphastar Pharmaceuticals by 18.2% during the third quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock worth $126,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.